Astellas Pharma Inc. and Chromocell Corporation collaborate for the development and commercialisation of therapeutics to treat neuropathic and other pain conditions.
Astellas obtains worldwide rights to commercialise CC8464 and back-up drug candidates to treat pain that have been identified through Chromocell’s Chromovert technology platform. Chromocell receives $15 million as an up-front payment and is eligible to receive over $500 million including development and commercial milestones, as well as double digit royalties on sales if CC8464 is successfully commercialised.
Chromocell will conduct all development of CC8464 through the initial phase 2a proof-of-concept clinical trial in neuropathic pain. Astellas will lead all further development activities through to commercialisation of CC8464 for the treatment of peripheral neuropathic pain. Aside from those development activities, Chromocell may propose, and may initiate, studies for certain additional indications such as rare diseases and non-oral formulations of the drug candidate.
NaV1.7 is an ion channel, involved in the transmission of pain. Chromocell’s lead compound, CC8464, is an oral, peripherally-acting inhibitor of NaV1.7 which may prove to be efficacious in several large unmet or poorly served chronic pain markets as well as rare, currently untreated diseases. Chromocell anticipates filing an IND for CC8464 in early 2016.
Subscribe to PharmaTutor News Alerts by Email >>
